GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » 3-Year Revenue Growth Rate

Invex Therapeutics (ASX:IXC) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics 3-Year Revenue Growth Rate?

Invex Therapeutics's Revenue per Share for the six months ended in Dec. 2024 was A$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of Invex Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Invex Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invex Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's 3-Year Revenue Growth Rate falls into.


;
;

Invex Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Invex Therapeutics  (ASX:IXC) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Invex Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Invex Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.

Invex Therapeutics Headlines

From GuruFocus

Verger Capital Management LLC Buys iShares Global Energy ETF, iShares Gold Trust

By GuruFocus Research GuruFocus Editor 10-29-2021

Fisher Asset Management Trims Infosys, Equinor Positions

By Tiziano Frateschi Tiziano Frateschi 02-07-2021

Ken Fisher's Top 4th-Quarter Trades

By Graham Griffin Graham Griffin 02-01-2021